Contract Award

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a new contract by an existing, large client. The project involves the use of our proprietary Virtual Tumour platform to model the client's targeted oncology agents in combination with other modalities to help inform dose and scheduling decisions. The value of the contract is £186k and it is anticipated that it will be completed over the course of the current calendar year. This project and associated contract award is the second of the two referred to in the Company's trading update on 3 May 2024 and now means that the Company will be going into its next financial year ending 30 June 2025 with committed revenues of over £0.5m.

Dr Peter Sargent, CEO, commented: "After many months of discussion and negotiation with the client, I'm delighted that we can now start this substantial project. This win reflects the significant experience and expertise the Physiomics team has built up over the years, in particular around more complex modelling of combination therapies".